These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8691618)

  • 21. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
    Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
    Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Early detection of pancreatic cancer by serum markers].
    Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K
    Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The value of tumor markers in digestive oncology].
    Ychou M; Rougier P; Bidart JM; Bellet D; Tigaud JM; Bohuon C
    Ann Chir; 1989; 43(7):517-23. PubMed ID: 2694905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markers for hepatocellular carcinoma.
    Wu AH; Sell S
    Immunol Ser; 1990; 53():403-22. PubMed ID: 1713067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F; Roscher R; Beger HG
    Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
    Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
    Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor markers in internal medicine hepatology].
    Vogel W; Judmaier G
    Wien Klin Wochenschr; 1989 Jul; 101(14):484-9. PubMed ID: 2549732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CA19-9].
    Odagiri E
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():642-4. PubMed ID: 16149600
    [No Abstract]   [Full Text] [Related]  

  • 33. [Histopathology and tumor markers].
    Kijima H; Ueyama Y; Osamura Y
    Rinsho Byori; 2003 Dec; 51(12):1203-15. PubMed ID: 14743744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of tumor cells in peritoneal lavages from patients with gastrointestinal cancer by multiplex reverse transcriptase PCR.
    Schmidt P; Thiele M; Rudroff C; Vaz A; Schilli M; Friedrich K; Scheele J
    Hepatogastroenterology; 2001; 48(42):1675-9. PubMed ID: 11813599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas.
    Enjoji M; Nakashima M; Yamaguchi K; Kotoh K; Nakamuta M
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1143-8. PubMed ID: 16048560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [2 --> 6 sialyl Le(a) antigen].
    Miyazaki K; Kannagi R
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():703-8. PubMed ID: 20960854
    [No Abstract]   [Full Text] [Related]  

  • 38. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical significance of Span-1 antigen assay as a tumor marker].
    Satake K; Chung YS; Umeyama K
    Nihon Rinsho; 1990 Feb; 48 Suppl():1053-6. PubMed ID: 2355504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.